May 2022

Make us laugh by sharing your best original jokes, memes and videos to be in with a chance to win a £100 cash prize! Make sure you enter before 26 January 2025 - the punnier, the better.

Hannah Roughley begins her new series on animal research with an explanation of the 3Rs, one of the key pillars of this important part of drug research and development. This series will explore the 3Rs in further detail and explore the ethical implications and considerations of animal research.

BPS Content Board Editor Bartosz Pajak explores the groundbreaking work of Alice Augusta Ball, and how her work is being retroactively credited to her, after she was largely unrecognised in her lifetime and in the period after her untimely death. 

Daniel Saffer's article on osteoarthritis treatments is the winner of the 2024 ECP Writing Prize. 

Nanthana Gunathilagan is the runner up for the 2024 ECP Writing Prize. Judges felt her detailed article on bioprospecting put a spotlight on an important topic.

Pharmacology Matters editors Taichi Ochi and Hannah Roughley look at Semaglutide, more widely known as Ozempic, its mechanism of action and recent rise in popularity among celebrities and the wider public.

Editor-in-Chief Prof Steve Tucker and Managing Editor Chloe Gynne outline the upcoming changes to how BPS content is published, and how you can get involved.

The BPS Events team talk about how they organised a world congress, and how their learnings will inform the delegate experience at Pharmacology 2024.

Joshua Dignam and Rosemary Gaw offer some tips to anyone looking to develop their confidence and skills when it comes to communicating your research.

Members of BPS' Council team explore the ways in which membership can use their voice and skills to enhance the work being done at the Society.

Almost everyone now knows about endorphins, brain neurotransmitters whose release is invariably invoked when someone is describing the sensation of pleasure. But few know that the first endorphins were isolated and characterised at the Unit for Research on Addictive Drugs (URAD) in Aberdeen, Scotland way back in 1975.